Loading
Immunotherapy and Immune Responses / Monoclonal and Polyclonal Antibodies Research / HER2/EGFR in Cancer Research · Journal article
Frontiers in Oncology · September 9, 2026
A consensus or society position rather than new primary data.
This narrative review examines the clinical potential of bispecific antibodies (BsAbs) as a therapeutic class in gastrointestinal oncology, highlighting mechanisms including T-cell redirection, dual checkpoint inhibition, and stromal remodeling across multiple GI malignancies. The authors argue that recent regulatory approval of zanidatamab and emergence of late-phase studies support BsAbs as an evolving platform to address immunotherapy resistance in biomarker-defined populations.
Narrative review. Patients with gastrointestinal cancers including colorectal, gastric, gastroesophageal, hepatocellular, pancreatic, biliary tract, esophageal, and neuroendocrine cancers.
HER2-targeted zanidatamab has received regulatory approval Multiple late-phase clinical studies of bispecific antibodies are ongoing across gastrointestinal malignancies Bispecific antibodies enable mechanisms such as T-cell redirection, dual checkpoint inhibition, and combined immune and anti-angiogenic modulation
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians and researchers in GI oncology should view this review as an expert synthesis of the emerging bispecific antibody platform as a potential component of precision immunotherapy for GI malignancies resistant to conventional checkpoint inhibitors. Specific clinical application awaits results from identified late-phase trials.
A narrative review synthesizing biological rationale, mechanisms, and current clinical evidence for bispecific antibodies across gastrointestinal cancers, offering expert perspective on therapeutic potential and future directions rather than reporting a primary clinical trial result.
As stated by the source record.
Clinicians and researchers in GI oncology should view this review as an expert synthesis of the emerging bispecific antibody platform as a potential component of precision immunotherapy for GI malignancies resistant to conventional checkpoint inhibitors. Specific clinical application awaits results from identified late-phase trials.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Gastrointestinal (GI) cancers remain a leading cause of cancer-related morbidity and mortality worldwide despite major advances in systemic therapy. Although immune checkpoint inhibitors have improved outcomes in selected biomarker-defined populations, most GI malignancies, including microsatellite-stable colorectal cancer, pancreatic ductal adenocarcinoma, and many biliary tract tumors, remain largely resistant because of low tumor immunogenicity, stromal exclusion, immune suppression, and adaptive resistance mechanisms. Bispecific antibodies (BsAbs) have emerged as a rapidly expanding class of immunotherapeutics capable of simultaneously engaging two distinct targets, enabling mechanisms such as T-cell redirection, dual checkpoint inhibition, combined immune and anti-angiogenic modulation, tumor-selective co-stimulation, and stromal remodeling. Recent clinical advances, including the approval of HER2-targeted zanidatamab and the emergence of multiple late-phase studies across GI malignancies, have validated the therapeutic potential of this platform. This review examines the biological rationale, structural formats, and mechanisms of action of BsAbs and summarizes current clinical evidence across colorectal, gastric, gastroesophageal, hepatocellular, pancreatic, biliary tract, esophageal, and neuroendocrine cancers. We also discuss emerging therapeutic targets, biomarker-driven patient selection, safety considerations, combination strategies, manufacturing challenges, and future directions. Collectively, current evidence suggests that BsAbs are poised to become an increasingly important component of precision immunotherapy, with the potential to overcome key limitations of conventional immunotherapeutic approaches in GI oncology.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.